Literature DB >> 3002679

Cushing's syndrome.

T A Howlett, L H Rees, G M Besser.   

Abstract

Cushing's syndrome remains one of the most challenging problems in clinical endocrinology. Cushing's disease is caused in the majority of cases by basophil pituitary microadenomas which may be successfully treated by trans-sphenoidal hypophysectomy. Treatment with metyrapone or o,p'-DDD can always induce a clinical remission but not a cure, and neurotransmitter therapy may be effective in a minority of cases. Pituitary irradiation cures about half of cases in the long-term and may be used for surgical failures. Tumours producing ectopic ACTH are frequently benign, small and occult and may produce a syndrome clinically indistinguishable from Cushing's disease. Biochemical investigations cannot absolutely distinguish pituitary from ectopic sources of ACTH and therefore body CT scanning and percatheter venous sampling are essential diagnostic investigations. Tumour localization may result in resection and complete cure, although even small tumours may have a malignant potential. Adrenal tumours are readily diagnosed by plasma ACTH measurement and adrenal CT scanning. Adrenal adenomas are cured by adrenalectomy. Carcinomas may be treated by a combination of adrenalectomy, radiotherapy and o,p'-DDD, but long-term prognosis is poor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002679     DOI: 10.1016/s0300-595x(85)80083-9

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  18 in total

1.  The modulation of glucocorticoid receptor content by 3-O-methyl-D-glucose transport in human mononuclear leukocyte in obesity.

Authors:  M Güven; H Hatemi; E Taşan; Y Altuntaş; T Ulutin; V Tezcan; G Kanigür-Sultuybek
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

2.  Cushing's disease and craniopharyngioma.

Authors:  F M Ackland; R Stanhope; M A Preece
Journal:  Arch Dis Child       Date:  1987-10       Impact factor: 3.791

3.  Ectopic cushing's syndrome caused by an 8 mm lung carcinoid localized by scintigram with the somatostatin analog111in-pentetreotide.

Authors:  João Filipe Raposo; Maria João Bugalho; Luís Gonçalves Sobrinho; Maria Conceição Pefeira; José Boavida; Margarida Loureiro; Maria Rosario Vieira; José Duro da Costa; José Manuel; Mendes Almeida; Kaiman Kovacs
Journal:  Endocr Pathol       Date:  1994-09       Impact factor: 3.943

4.  The corticotropin-releasing factor test in the diagnosis of ectopic ACTH secretion.

Authors:  E Cagliero; M Lorenzi
Journal:  West J Med       Date:  1987-05

5.  LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice.

Authors:  Rucha Patel; Monika Patel; Ricky Tsai; Vicky Lin; Angie L Bookout; Yuan Zhang; Lilia Magomedova; Tingting Li; Jessica F Chan; Conrad Budd; David J Mangelsdorf; Carolyn L Cummins
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 6.  Treating Cushing's disease.

Authors:  W J Jeffcoate
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

7.  Evaluation of antioxidant systems in pituitary-adrenal axis diseases.

Authors:  A Mancini; E Leone; A Silvestrini; R Festa; V Di Donna; L De Marinis; A Pontecorvi; G P Littarru; E Meucci
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

8.  Spontaneous globe luxation in iatrogenic Cushing syndrome.

Authors:  Leticia Ortega-Evangelio; Javier Navarrete-Sanchis; Basil K Williams; Juan Miguel Tomas-Torrent
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-08-09       Impact factor: 3.117

9.  G6PC2 Modulates the Effects of Dexamethasone on Fasting Blood Glucose and Glucose Tolerance.

Authors:  Kayla A Boortz; Kristen E Syring; Rebecca A Lee; Chunhua Dai; James K Oeser; Owen P McGuinness; Jen-Chywan Wang; Richard M O'Brien
Journal:  Endocrinology       Date:  2016-09-21       Impact factor: 4.736

Review 10.  Two types of ectopic Cushing syndrome or a continuum? Review.

Authors:  Marta Araujo Castro; Mónica Marazuela Azpiroz
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.